In order to determine 6'-O-caffeoylarbutin protection of type I diabetes in mice， mice were injected alloxan drugs to create type I diabetes model， and diabetic mice were also treated with 6'-O-caffeoylarbutin. Mice were randomly divided into 5 groups: normal control group， model group， positive control group， 6'-O-caffeoylarbutin low-dose group (100 mg/kg/d bw)， and 6'-O-caffeoylarbutin high-dose group (200mg/kg/d bw). After continuous intragastric administration for 4 weeks， glucose tolerance， organ index， serum index， liver and kidney indexes of mice in each group were measured， and pathological examination of pancreas， liver and kidney tissues was conducted. The results showed that the 6'-O-caffeoylarbutin can reduce type I diabetes mice serum total cholesterol， triglycerides， free fatty acid and low density lipoprotein cholesterol， high-density lipoprotein cholesterol and insulin levels. 6'-O-caffeoylarbutin can also increase the activity of superoxide dismutase， catalase and glutathione peroxidase in liver tissue， and reduce the content of malondialdehyde， alanine aminotransferase， alkaline phosphatase and urea nitrogen in kidney tissue. Conclusion: 6'-O-caffeoylarbutin has a certain hypoglycemic effect， and can effectively alleviate the injury of liver， kidney， pancreas and other tissues in type I diabetes mice.